Brain neoplasm
MONDO:0021211A neoplasm (disease) that involves the brain.
Also known as: brain neoplasm (disease), brain neoplasms, brain tumor, brain tumour, neoplasm of brain, neoplasm of the brain, tumor of brain, tumor of the Brain
2242 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Custom-Made cancer vaccine tested in 25 patients
⭐️ VACCINE ⭐️ CompletedThis study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.
Phase: PHASE1 • Sponsor: Aaron Miller • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising combo tackles tough cancers in early trial
Disease control CompletedThis early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Brain tumor trial delivers targeted toxin directly into tumors
Disease control CompletedThis phase 1 study tested a drug called D2C7-IT in 81 adults with recurrent malignant glioma (a type of brain tumor). The drug is a lab-made antibody linked to a toxin that targets specific proteins on tumor cells. It was infused directly into the tumor over 72 hours using thin t…
Phase: PHASE1 • Sponsor: Darell Bigner • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer drug combo tested in early human trial
Disease control CompletedThis early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…
Phase: PHASE1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a dementia drug shield kids' brains from radiation damage?
Disease control CompletedThis pilot study tested whether memantine, a drug used for dementia in adults, could help prevent memory and thinking problems in children receiving brain radiation for tumors like glioma or craniopharyngioma. 41 children aged 6-21 took either memantine or a placebo during radiat…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug IBI129 tested in humans for first time against Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Chemotherapy delivered straight to the brain: a new hope for recurrent tumors?
Disease control CompletedThis early-phase study tested a method called convection-enhanced delivery to pump the chemotherapy drug topotecan directly into brain tumors in 16 patients with recurrent malignant brain tumors. The goal was to see if this approach is safe and to find the best dose, while also m…
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase: PHASE1, PHASE2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in helping immune system fight advanced cancers
Disease control CompletedThis study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase: PHASE1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cocktail of three drugs tested for tough bladder cancers
Disease control CompletedThis early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combination therapy aims to outsmart aggressive childhood brain cancer
Disease control CompletedThis phase 3 trial investigates whether adding carboplatin and isotretinoin to standard radiation and chemotherapy improves outcomes for children and young adults with high-risk medulloblastoma, a fast-growing brain tumor. Participants receive radiation therapy along with several…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can less radiation still beat childhood brain cancer?
Disease control CompletedThis trial studies whether giving a lower dose of radiation to the brain and spine, along with a smaller radiation boost to the tumor site, works as well as standard radiation when combined with chemotherapy in children aged 3–7 with newly diagnosed standard-risk medulloblastoma.…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shot form of cancer drug tested in 142 patients
Disease control CompletedThis study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New vaccine hope for kids with deadly brain tumors
Disease control CompletedThis study tested a special vaccine made from the child's own immune cells (dendritic cells) to fight aggressive brain tumors like high-grade glioma and DIPG. Ten children received the vaccine alongside standard treatments. The goal was to see if the vaccine was safe, possible to…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Surgical flap opens door to brain tumors in small safety trial
Disease control CompletedThis study tested a new surgical technique in 12 patients with newly diagnosed glioblastoma, an aggressive brain cancer. Surgeons placed a tissue flap from the scalp into the brain tumor cavity to bypass the blood-brain barrier, which normally blocks many treatments. The main goa…
Phase: NA • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immunotherapy combo shows promise for tough pituitary tumors
Disease control CompletedThis phase 2 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 patients with aggressive pituitary tumors that worsened after surgery and radiation. The goal was to see if the combination could shrink tumors or slow their growth. Researchers also monitored side…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug XTX202 tested in patients with advanced cancers
Disease control CompletedThis study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to tackle childhood cancers that Won't quit
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…
Phase: PHASE1 • Sponsor: Peter Zage • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo tested for tough cancers
Disease control CompletedThis early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Immune cell boost shows promise against childhood cancers
Disease control CompletedThis early-phase trial tested whether giving activated natural killer (NK) cells, with or without a protein called rhIL15, is safe and feasible for children and young adults with solid tumors that didn't respond to other treatments. Sixteen participants received chemotherapy to l…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Real-World data shows Tirabrutinib's promise for rare brain cancer
Disease control CompletedThis study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see…
Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Radiation before brain surgery may stop cancer's return
Disease control CompletedThis study tested giving focused radiation before surgery to people with cancer that spread to the brain. The goal was to see if this approach is safe and might lower the chance of the tumor coming back. 26 adults with brain metastases took part. The treatment aims to control the…
Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…
Phase: PHASE1, PHASE2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental cancer drug injected directly into tumors shows early promise
Disease control CompletedThis early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New radiation dosing strategy aims to tame large brain metastases
Disease control CompletedThis phase I trial tested a special type of radiation called hypofractionated radiosurgery for people with large brain metastases (tumors that spread from other cancers). The goal was to find the safest and most effective dose while limiting damage to healthy brain tissue. Twenty…
Phase: NA • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug KL340399 tested in 21 patients
Disease control CompletedThis early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental drug targets Hard-to-Treat brain metastases
Disease control CompletedThis phase 2 trial tested a drug called patritumab deruxtecan (HER3-DXd) in 63 patients with breast cancer, lung cancer, or other solid tumors that had spread to the brain or the lining of the brain and spinal cord. The drug is designed to seek out and destroy cancer cells carryi…
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Brain cancer vaccine shows promise in early trial
Disease control CompletedThis early-phase study tested a personalized vaccine made from a patient's own immune cells (dendritic cells) combined with standard chemotherapy (temozolomide) for adults with newly diagnosed glioblastoma, an aggressive brain cancer. Eleven patients who had most of their tumor r…
Phase: PHASE1 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cancer drug HBM1020 tested in tiny early trial
Disease control CompletedThis early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…
Phase: PHASE1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase: PHASE1, PHASE2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Could extra chemo beat brain tumors in kids?
Disease control CompletedThis study looked at whether giving chemotherapy after radiation helps children with a type of brain tumor called ependymoma. About 479 children aged 1 to 21 took part. Some received radiation alone, while others also got a combination of chemotherapy drugs. The goal was to see i…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental antibody HH-101 tested in 12 patients with advanced cancers
Disease control CompletedThis early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…
Phase: PHASE1, PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy duo takes on deadly brain tumor in major trial
Disease control CompletedThis study compared standard radiation plus chemotherapy to radiation plus two immunotherapy drugs (ipilimumab and nivolumab) in 159 people with a newly diagnosed, aggressive brain cancer called MGMT-unmethylated glioblastoma. The goal was to see if the immunotherapy combination …
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to boost immune attack on deadly brain cancer
Disease control CompletedThis phase 2 trial tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy (temozolomide) improves survival in 47 adults with newly diagnosed glioblastoma or gliosarcoma. Participants had their tumors surgically removed and completed init…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug tested for advanced cancers: early results
Disease control CompletedThis early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…
Phase: PHASE1 • Sponsor: Idience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Drug shows promise for kidney cancer brain metastases in early trial
Disease control CompletedThis phase 2 trial tested the drug sunitinib in 21 patients with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors by blocking blood flow and cell growth. Researchers measured how many patients had a response after two treatment…
Phase: PHASE2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Sound waves + radiation: new hope for tough brain tumors?
Disease control CompletedThis small pilot study tested whether combining focused ultrasound with a second round of radiation is safe for people with recurrent glioblastoma, an aggressive brain cancer. Seven adults who had already tried standard treatments received the combination therapy. The goal was to…
Phase: NA • Sponsor: NaviFUS Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Sound waves may help deliver brain tumor drug
Disease control CompletedThis pilot study tested a device called NaviFUS that uses focused ultrasound to temporarily open the blood-brain barrier, combined with the drug bevacizumab (Avastin), in 6 patients with recurrent glioblastoma (a type of brain cancer). The goal was to see if the combination is sa…
Phase: NA • Sponsor: NaviFUS Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for tough breast cancers: drug combo targets tumors in body and brain
Disease control CompletedThis phase 2 trial tested whether adding the drug veliparib to standard chemotherapy (cisplatin) helps people with metastatic triple-negative or BRCA-related breast cancer, including those with brain metastases. The study enrolled 344 participants to see if the combination slows …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo tested on brain tumors before surgery
Disease control CompletedThis early study tested whether giving a single dose of nivolumab with either ipilimumab or relatlimab before surgery is safe and possible for people with melanoma that has spread to the brain. Only one person took part, so results are very limited. The goal was to see how the dr…
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple-Drug immunotherapy cocktail shows promise in advanced tumors
Disease control CompletedThis early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Phase: PHASE2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Triple immunotherapy cocktail shows promise against tough cancers
Disease control CompletedThis study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Diabetes drug plus chemo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Early trial checks safety of experimental cancer drug
Disease control CompletedThis early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise against advanced cancers in early trial
Disease control CompletedThis study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New radiation approach aims to tame pituitary tumors with fewer side effects
Disease control CompletedThis study tested a new way of delivering radiation for people with non-secreting pituitary adenomas that came back or remained after surgery. Instead of a single high dose, the radiation was given in five smaller daily doses. The goal was to see if this approach could control tu…
Phase: NA • Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Generic cancer pill matches Brand-Name drug in study
Disease control CompletedThis study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…
Phase: NA • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Brain surgery breakthrough? sedative may shield the brain!
Disease control CompletedThis study looked at whether a sedative called dexmedetomidine can protect the brain during surgery to remove a brain tumor. 56 adults having brain tumor surgery received either the drug or a placebo. The goal was to see if the drug reduces brain damage and inflammation, helping …
Phase: PHASE4 • Sponsor: Georgia Tsaousi • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New approach: radiation first, then surgery for brain tumors
Disease control CompletedThis pilot study tested whether giving gamma knife radiation before surgery for brain metastases is safe and feasible. Eleven adults with 1 to 4 brain tumors took part. The goal was to see how many patients could have surgery after radiation and how many had no visible tumor left…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Sound waves may help deliver cancer drugs to the brain
Disease control CompletedThis study tested whether a device that uses focused ultrasound can safely and temporarily open the blood-brain barrier in people with HER2-positive breast cancer that has spread to the brain. Eight participants received the procedure, and researchers checked for side effects and…
Phase: NA • Sponsor: InSightec • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cancer drug ZN-c3 shows early promise in solid tumor trial
Disease control CompletedThis early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…
Phase: PHASE1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New immunotherapy combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a statin and arthritis drug tame childhood brain cancer?
Disease control CompletedThis early-phase trial tested a combination of two drugs—fluvastatin (a cholesterol-lowering statin) and celecoxib (an arthritis drug)—in 20 children and young adults with certain brain tumors (gliomas) that had come back or not responded to treatment. The goal was to find the sa…
Phase: PHASE1 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control CompletedThis study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill takes on stomach cancer in first human trial
Disease control CompletedThis study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo therapy tested for deadly childhood brain cancer
Disease control CompletedThis early-phase study tested whether adding the drug cilengitide to standard radiation is safe for children and young adults with a rare, aggressive brain tumor called DIPG. The main goal was to find the highest safe dose. 32 participants were enrolled. The study did not aim to …
Phase: PHASE1 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cancer drug RS-0139 tested in humans for first time
Disease control CompletedThis early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…
Phase: PHASE1 • Sponsor: RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Two-Drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy shows promise for brain metastases
Disease control CompletedThis early study tested combining the immunotherapy drug pembrolizumab with precise radiation (stereotactic radiosurgery) in 25 people with melanoma or lung cancer that had spread to the brain. The main goal was to check for serious side effects. Researchers also tracked how long…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Proton beam therapy shows promise in tumor control trial
Disease control CompletedThis study tested the Varian ProBeam proton therapy system in 47 people with solid tumors. The goal was to see if the device safely controls tumors and meets performance standards. Patients received proton radiation and were followed for up to 5 years after treatment.
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Radiation before brain surgery shows promise in early trial
Disease control CompletedThis study tested a new approach for people with large brain metastases (tumors that spread from other cancers). Instead of the usual surgery followed by radiation, patients received focused radiation first, then surgery. The goal was to see if this order reduces side effects and…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested the safety of combining two drugs—AZD1775 (a pill) and durvalumab (an IV infusion)—in 56 adults with advanced solid tumours that had stopped responding to standard treatments. The goal was to find safe doses and watch for side effects. While not a cu…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Targeted pill shows promise for rare genetic cancers
Disease control CompletedThis study tested an experimental drug called ENV-101 (taladegib) in 20 adults with advanced solid tumors that have a specific genetic mutation (PTCH1 loss-of-function). The drug works by blocking a growth pathway in cancer cells. Researchers measured how many patients' tumors sh…
Phase: PHASE2 • Sponsor: Endeavor Biomedicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Glow-in-the-Dark drug could help brain cancer surgery
Disease control CompletedThis completed Phase III trial tested a drug called 5-aminolevulinic acid (5-ALA) in 86 adults with malignant brain glioma. Patients took the drug orally before surgery, causing tumor cells to glow under a special light. This helps surgeons see and remove more cancerous tissue. T…
Phase: PHASE3 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy tackles rare brain cancer spread
Disease control CompletedThis early-phase trial tested the drug avelumab (Bavencio) combined with whole-brain radiotherapy in 16 patients with leptomeningeal disease, a condition where cancer spreads to the lining of the brain and spinal cord. The main goal was to find a safe dose and check for side effe…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for kids with resistant cancers? drug combo shows promise in early trial
Disease control CompletedThis study tested the safety and effectiveness of the drug abemaciclib combined with other cancer medicines in 47 children and young adults whose solid tumors (including neuroblastoma) had stopped responding to standard treatments. The goal was to find the best dose and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New shot aims to stop Chemo's dangerous side effect
Disease control CompletedThis early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New targeted pill shows promise for Hard-to-Treat bile duct cancers
Disease control CompletedThis study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo shows promise in controlling advanced cancers
Disease control CompletedThis study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for recurrent brain cancer? early trial targets immune suppression
Disease control CompletedThis early-phase study tested a combination of two drugs (low-dose capecitabine and bevacizumab) in 12 people whose glioblastoma brain tumor had come back or continued growing despite prior treatment. The goal was to see if the drugs could reduce certain immune cells (MDSCs) that…
Phase: PHASE1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill targets brain tumors with IDH mutations
Disease control CompletedThis early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug AMG 305 tested in patients with advanced cancers
Disease control CompletedThis early-phase study tested a new drug called AMG 305 in 37 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Participants received the drug and were mo…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Tailored tumor attack: can custom drug cocktails beat recurrent glioblastoma?
Disease control CompletedThis pilot study tested whether it's possible to quickly create and start a personalized drug combination for each patient with recurrent glioblastoma, a serious brain cancer. Researchers used genetic testing on tumor tissue to pick drugs that target specific mutations. The study…
Phase: PHASE1 • Sponsor: Jennifer Clarke • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for kids with resistant tumors? early trial tests CUDC-907
Disease control CompletedThis early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side ef…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New radiation approach shows promise for controlling small brain metastases
Disease control CompletedThis study tested a precise type of radiation called fractionated stereotactic radiotherapy (FSRT) in 33 adults with 1 to 4 small brain metastases (each 2 cm or smaller). The goal was to see if this approach could control the tumors while avoiding serious side effects like radiat…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New oral drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose f…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cancer pill tested in humans for first time
Disease control CompletedThis early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…
Phase: PHASE1 • Sponsor: Godavari Biorefineries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New nanoparticle chemo shows promise in early trial for tough cancers
Disease control CompletedThis early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…
Phase: PHASE1 • Sponsor: SN BioScience • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase: PHASE1, PHASE2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for tough cancers: revumenib trial shows promise
Disease control CompletedThis early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New hope for toddlers with brain cancer: stem cell rescue trial
Disease control CompletedThis study looked at 91 children under 3 years old with aggressive brain tumors. It compared two intense chemotherapy plans, one with and one without methotrexate, followed by a stem cell transplant. The goal was to see which approach led to more complete tumor disappearance.
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden brain tumors
Disease control CompletedThis completed Phase 1 trial tested whether a dye called indocyanine green (ICG) can make brain tumor cells glow during surgery, helping surgeons see and remove them more completely. 363 adults with brain tumors received an ICG injection before surgery, and special cameras captur…
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat solid tumors
Disease control CompletedThis pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental immune therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Chemo-Immuno cocktail shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…
Phase: PHASE1, PHASE2 • Sponsor: Kristoffer Rohrberg • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for kids with rare cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called avapritinib in 29 children aged 2 to 18 with advanced solid tumors that have specific genetic changes (KIT or PDGFRA). The goal was to see if the drug is safe and can shrink or control the tumors. Participants took the drug by mouth, and researcher…
Phase: PHASE1, PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise for Hard-to-Treat cancers with p53 gene
Disease control CompletedThis study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …
Phase: PHASE1, PHASE2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug JAB-8263 tested in patients with advanced cancers
Disease control CompletedThis early-phase study tested a new drug called JAB-8263 in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study is now complete.
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer drug MRX-2843 enters first human trial
Disease control CompletedThis early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Immunotherapy duo shows promise against brain metastases in melanoma
Disease control CompletedThis study tested a combination of two immunotherapy drugs, low-dose ipilimumab and pembrolizumab, in 24 people with advanced melanoma that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors and improve survival. Participants receiv…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental antibody combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug shows promise in early trial for kids with deadly brain cancer
Disease control CompletedThis early-phase study tested an experimental drug called INCB7839 in 13 children whose high-grade gliomas (aggressive brain tumors) had come back or worsened after standard treatment. The main goals were to find a safe dose and check for side effects. The drug works by blocking …
Phase: PHASE1 • Sponsor: Pediatric Brain Tumor Consortium • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New immune booster FL115 tested in patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, wh…
Phase: PHASE1 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug IBI334 tested on 28 patients with advanced cancer
Disease control CompletedThis study tested a new drug called IBI334 in 28 people with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to check the drug's safety and see if it helps control the cancer. The study is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug ZGGS15 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…
Phase: PHASE1 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called JAB-BX102, alone or with the immunotherapy pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also …
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill shows promise in early trial for tough cancers
Disease control CompletedThis early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …
Phase: PHASE1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Second radiation blast shows promise for tough brain cancer
Disease control CompletedThis study tested giving a second round of radiation to people whose glioblastoma (a fast-growing brain tumor) came back after standard treatment. Seventeen adults aged 18 to 50 received daily radiation for 2-3 weeks. The goal was to find the safest highest dose and see how it af…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Heat and immune boost: new combo tackles Hard-to-Treat cancers
Disease control CompletedThis trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…
Phase: PHASE1, PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill JAB-3312 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New cancer pill shows promise in early trial
Disease control CompletedThis early-phase study tested a new oral drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. LP-118 works by blocking two proteins that help cancer cells survive. The main goals were to find a safe dose and c…
Phase: PHASE1 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug NB003 tested in 258 patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…
Phase: PHASE1 • Sponsor: Ningbo Newbay Technology Development Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug RC88 shows promise for advanced cancers in early trial
Disease control CompletedThis study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.
Phase: PHASE1, PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor respons…
Phase: PHASE1 • Sponsor: Ascletis Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New cancer drug shows promise in early human trial
Disease control CompletedThis early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo tested for advanced cancers in asian patients
Disease control CompletedThis early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…
Phase: EARLY_PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. While not a cure, the study…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug shows promise for lung cancer brain metastases
Disease control CompletedThis phase 2 trial tested the drug furmonertinib in 24 people with advanced non-small cell lung cancer (NSCLC) that has EGFR mutations and spread to the brain. The goal was to see how long the drug could keep brain tumors from growing. Participants took a daily pill, and research…
Phase: PHASE2 • Sponsor: Peking Union Medical College • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Immune cells injected directly into brain show promise for kids with tough tumors
Disease control CompletedThis early-stage study tested a new treatment for children and young adults with brain tumors that came back or didn't respond to standard therapy. Doctors took the patients' own immune cells, modified them to recognize a protein called EGFR on tumor cells, and injected them dire…
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug E7090 tested in patients with advanced solid tumors
Disease control CompletedThis early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New proton beam machine shows promise in tumor control trial
Disease control CompletedThis study tested a new proton therapy device, the Varian ProBeam360°, in 47 people with solid tumors. The goal was to see if it could control tumor growth with few severe side effects. Participants received radiation for 1 to 8 weeks and were followed for up to 5 years. The main…
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New cancer drug ABBV-155 enters first human tests
Disease control CompletedThis early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Glowing tumor surgery: new hope for kids with brain cancer?
Disease control CompletedThis study tested a drug called 5-ALA in 78 children with brain tumors. The drug makes tumor cells glow under a special light during surgery, helping surgeons remove more of the tumor while avoiding healthy brain. The main goal was to check if the drug is safe for children. Resea…
Phase: PHASE2 • Sponsor: Universität Münster • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New antibody drug tested in patients with Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BAT6026 in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New cancer drug shows promise in early safety trial
Disease control CompletedThis early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New immunotherapy cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug duo shows early promise against advanced cancers
Disease control CompletedThis early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for s…
Phase: EARLY_PHASE1 • Sponsor: Akesobio Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New combo therapy targets breast cancer brain metastases in early trial
Disease control CompletedThis early-phase study tested whether combining stereotactic radiosurgery (precise radiation) with the immunotherapy drug nivolumab (Opdivo) is safe and can shrink tumors in people with breast cancer that has spread to the brain. Fourteen participants received the combination. Th…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New radiation strategy before brain surgery shows promise
Disease control CompletedThis study tested giving a precise, high-dose radiation treatment (stereotactic radiosurgery) to brain metastases before surgical removal. The goal was to see if this approach improves local control at 6 months. The trial enrolled 70 adults with up to 4 brain metastases from cert…
Phase: PHASE2 • Sponsor: Centre Jean Perrin • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New cancer drug GEN1056 tested in first human trial
Disease control CompletedThis early-stage trial tested a new drug, GEN1056, in 26 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors.
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could less radiation be enough? new trial tests tailored therapy for kids with brain tumors
Disease control CompletedThis phase 2 trial tested whether children with localized central nervous system germ cell tumors could safely receive lower doses of radiation after chemotherapy. The study enrolled 262 children and used response to chemotherapy to decide the radiation dose. The goal was to main…
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cocktail aims to shrink deadly brain tumors
Disease control CompletedThis phase 2 trial tested a combination of two drugs (retifanlimab and epacadostat) plus radiation and bevacizumab in 51 patients with recurrent glioblastoma, an aggressive brain cancer. The goal was to boost the immune system's attack on the tumor and improve survival. The study…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cancer drug BR101 enters first human tests
Disease control CompletedThis early-phase trial tested a new drug called BR101 in 15 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receiv…
Phase: PHASE1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New immunotherapy combo shows promise for advanced cancers
Disease control CompletedThis study tested an experimental drug called BMS-986249, either alone or combined with the immunotherapy nivolumab (Opdivo), in 356 people with advanced solid tumors. The main goals were to check safety and find the right dose. Researchers also looked at whether the tumors shran…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New triple therapy shows promise for resistant cancers
Disease control CompletedThis early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New combo therapy for aggressive brain cancer shows promise in early trial
Disease control CompletedThis study tested whether adding whole brain radiation and a drug called plerixafor to the usual chemotherapy and radiation could help people with a fast-growing brain tumor called glioblastoma. 21 patients took part. The goal was to see if the combination could delay tumor growt…
Phase: PHASE2 • Sponsor: Lawrence D Recht • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Early trial of BDB018 combo for tough cancers wraps up with just one patient
Disease control CompletedThis early-phase study tested a new immunotherapy drug called BDB018, given alone or with pembrolizumab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Only one person took part, …
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New antibody drug takes on Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New hope for kids with gigantism: daily shot may tame growth hormone
Disease control CompletedThis study tested a drug called pegvisomant in children aged 2 to 18 with gigantism, a condition where the body makes too much growth hormone. The goal was to see if the drug could safely lower hormone levels and slow down abnormal growth. Participants received daily injections a…
Phase: PHASE3 • Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug aims to boost immune system against tough cancers
Disease control CompletedThis early-phase trial tested a new drug called HCW9218 in 18 people with advanced solid tumors that had not responded to at least two prior treatments. The drug is designed to both activate immune cells and block signals that help tumors grow. The main goal was to find a safe do…
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can more radiation sessions tame large brain tumors safely?
Disease control CompletedThis study tested whether giving higher doses of radiation over five sessions is safe for people with brain metastases that are 2 to 6 cm in size. These larger tumors are often too risky for a single high-dose treatment. The trial enrolled 13 adults and aimed to find the highest …
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control CompletedThis study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Electric field device shows promise for lung cancer brain spread
Disease control CompletedThis study tested whether a portable device that creates low-intensity electric fields (called Tumor Treating Fields, or TTFields) can help control brain tumors that have spread from non-small cell lung cancer. 298 adults with 1 to 10 brain metastases received standard radiosurge…
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
App helps young cancer survivors shed pounds
Disease control CompletedThis study tested a smartphone app to help young adult cancer survivors (ages 18-39) lose weight. The app tracked diet and activity as part of a behavioral weight loss program. The goal was to see if this approach was practical and well-liked by participants. The study involved 6…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New immunotherapy DF9001 targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…
Phase: PHASE1, PHASE2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New antibody combo tested in advanced cancer patients
Disease control CompletedThis early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and se…
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…
Phase: PHASE1 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental cocktail targets deadly brain cancer in early trial
Disease control CompletedThis early-phase trial tested the safety of adding two drugs, pembrolizumab and vorinostat, to standard chemotherapy and radiation for people newly diagnosed with glioblastoma, an aggressive brain cancer. The study enrolled 21 participants to find the highest safe dose of vorinos…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage study tested a new drug (BI 836880) alone and with another drug (BI 754091) in 21 Japanese patients with advanced solid tumors. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug shows promise for cortisol disorder
Disease control CompletedThis study tested an experimental drug called SPI-62 in 26 adults with Cushing's syndrome caused by a non-adrenal tumor. The goal was to see if SPI-62 could lower cortisol levels safely. Participants received either SPI-62 or a placebo for 24 weeks, with an option to continue lon…
Phase: PHASE2 • Sponsor: Sparrow Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for kids with brain tumors: targeted pill shows promise
Disease control CompletedThis study tested a drug called MEK162 in 105 children with low-grade gliomas or other tumors that have a specific overactive growth signal. The goal was to find the best dose, check for side effects, and see if the drug could shrink tumors. Children took the drug by mouth twice …
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug AMG 256 tested in patients with hard-to-treat cancers
Disease control CompletedThis early-phase study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that could not be cured by standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Researchers monitored side effects and how the…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug combo aims to boost immune system against Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental drug combo takes on tough cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to chec…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental cocktail targets tough lung cancer
Disease control CompletedThis early-phase trial tested a four-drug combination (entinostat, atezolizumab, carboplatin, and etoposide) in 3 people with extensive-stage small cell lung cancer that had not been treated before. The goal was to find a safe dose and see if the combination could be given for at…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for young cancer patients: drug shows promise against tough tumors
Disease control CompletedThis study tested the drug lenvatinib in 127 children, adolescents, and young adults whose solid tumors had come back or stopped responding to treatment. The goal was to see if the drug could shrink tumors and to check for side effects. Participants received lenvatinib daily, and…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Proton beam zaps liver tumors: new hope for cancer patients?
Disease control CompletedThis study tested a precise type of radiation called proton beam therapy for people whose cancer has spread to the liver. 92 adults with 1 to 4 liver tumors received this treatment. The goal was to see if it could stop tumor growth and cause fewer side effects than standard radia…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new drug called BI 836880 in 24 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug shows early promise in small safety trial
Disease control CompletedThis early-phase trial tested a new drug called BI 836880 in 29 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find a safe dose and check for side effects. The study was not designed to cure cancer, but to gather information …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug combo shows promise in early trial
Disease control CompletedThis early-phase trial tested two experimental drugs, BNT152 and BNT153, alone and together in 86 adults with advanced solid tumors that had spread or could not be removed and had no standard treatment options. The main goal was to check safety and find the best dose. Researchers…
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer cocktail shows promise in early human trial
Disease control CompletedThis early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for brain cancer: immune drug combo shows promise
Disease control CompletedThis study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and radiation helps people with newly diagnosed glioblastoma, an aggressive brain cancer. About 60 participants received the combination to see if it improves survival and controls the d…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Triple-Drug cocktail shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a combination of three drugs—selinexor, nivolumab, and ipilimumab—in 11 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The main goal was to check the safety and tolerability of the combination, whi…
Phase: PHASE1 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Immunotherapy combo shows promise for chinese cancer patients
Disease control CompletedThis study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients with advanced solid tumors that had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. The trial is now comple…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 17:18 UTC
-
New combo therapy targets Hard-to-Treat tumors
Disease control CompletedThis early-phase trial tested a new drug called RiMO-301, injected directly into tumors, along with standard radiation. It involved 32 people with advanced cancers that could not be cured. The main goal was to find a safe dose and check for any early signs of tumor shrinkage.
Phase: PHASE1 • Sponsor: Coordination Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:16 UTC
-
Radiation showdown: which schedule beats childhood brain cancer?
Disease control CompletedThis trial tested two different ways of giving radiation to children and teens with a standard-risk brain tumor called medulloblastoma. One group got standard daily radiation, while the other got smaller doses twice a day. The goal was to see which schedule better prevents the ca…
Phase: PHASE3 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 26, 2026 17:03 UTC
-
New pill shows promise against lung cancer brain metastases
Disease control CompletedThis study tested a new drug called AZD3759 against standard targeted therapies (erlotinib or gefitinib) in 492 people with advanced EGFR-mutant lung cancer that had spread to the brain. The goal was to see if AZD3759, which is designed to better reach the brain, could keep the c…
Phase: PHASE2, PHASE3 • Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:13 UTC
-
New pill plus immunotherapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…
Phase: PHASE1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called LM-108, alone or combined with another immunotherapy, in 78 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers als…
Phase: PHASE1, PHASE2 • Sponsor: LaNova Australia Pty Limited • Aim: Disease control
Last updated Jun 26, 2026 15:31 UTC
-
New radioactive therapy shows promise in early trial for tough cancers
Disease control CompletedThis early-phase trial tested a new radioactive drug called 177Lu-LNC1004 in 11 adults with advanced solid tumors that had stopped responding to standard treatments. The drug targets a protein (FAP) found on many cancer cells, delivering radiation directly to the tumor. The main …
Phase: PHASE1 • Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD. • Aim: Disease control
Last updated Jun 26, 2026 15:15 UTC
-
Brain surgery breakthrough? diaphragm zap may cut delirium risk
Disease control CompletedThis study tested whether using a device to stimulate the diaphragm (the main breathing muscle) during brain surgery could lower the risk of postoperative problems like confusion (delirium) and lung issues. Researchers enrolled 120 adults undergoing brain tumor removal. Half rece…
Phase: NA • Sponsor: Beijing Sanbo Brain Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:13 UTC
-
New combo therapy targets tough brain tumors
Disease control CompletedThis phase 2 trial tested a drug called VAL-083 combined with standard radiation in 29 people with newly diagnosed glioblastoma, a fast-growing brain cancer. The study focused on patients whose tumors have a specific genetic marker (unmethylated MGMT) that makes them resistant to…
Phase: PHASE2 • Sponsor: Kintara Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:06 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
New cancer drug EVT801 tested in humans for first time
Disease control CompletedThis early-stage trial tested an experimental drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose to use in future studies. Participants took EVT801 cap…
Phase: PHASE1 • Sponsor: Kazia Therapeutics Limited • Aim: Disease control
Last updated Jun 26, 2026 13:12 UTC
-
Can a 1950s antipsychotic help fight glioblastoma?
Disease control CompletedThis early-stage trial tested whether adding chlorpromazine, an old antipsychotic drug, to standard treatment (radiation and chemotherapy) is safe for people newly diagnosed with glioblastoma, an aggressive brain cancer. Ten adults took part. The main goal was to find a safe dose…
Phase: PHASE1 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated Jun 26, 2026 13:07 UTC
-
AI reads MRI scans to spot brain tumors without surgery
Diagnosis CompletedThis study tests whether an artificial intelligence system called GliomaAI-Astro23 can identify a specific type of brain tumor (IDH mutant astrocytoma) from routine MRI scans. Researchers are using existing MRI data from 1,372 patients to train and evaluate the AI. If accurate, t…
Sponsor: Deep Learning Institute of Radiological Sciences • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
AI reads MRI scans to spot a deadly brain tumor type without surgery
Diagnosis CompletedThis study tests whether an artificial intelligence system called GliomaAI-Astro4 can accurately detect a specific type of brain tumor (IDH mutant astrocytoma grade 4) using routine MRI scans. Researchers will analyze previously collected, anonymized MRI data from 1,372 patients …
Sponsor: Deep Learning Institute of Radiological Sciences • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
AI reads brain scans to spot deadly tumors without surgery
Diagnosis CompletedThis study tests whether an artificial intelligence system called GliomaAI-GBM can detect a specific aggressive brain tumor (IDH wildtype glioblastoma) using routine MRI scans. Researchers will analyze previously collected, anonymized MRI data from 1,372 patients across 13 hospit…
Sponsor: Deep Learning Institute of Radiological Sciences • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
Artificial intelligence reads brain scans to detect hidden tumor type
Diagnosis CompletedThis study tests whether an artificial intelligence system called GliomaAI-Oligo can detect a specific type of brain tumor (oligodendroglioma) from routine MRI scans. Researchers will use over 1,300 existing, anonymized scans from multiple hospitals to train and evaluate the AI. …
Sponsor: Deep Learning Institute of Radiological Sciences • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
New Sugar-Based tracer could spot brain tumors on SPECT scans
Diagnosis CompletedThis study tested a radioactive sugar-like tracer called 99mTc-1-thio-D-glucose to see if it can make brain tumors visible on SPECT scans. Sixteen adults with primary or recurrent brain tumors received one injection, then had scans at several time points. Researchers measured how…
Phase: PHASE1, PHASE2 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
Artificial intelligence reads brain scans to detect deadly tumors
Diagnosis CompletedThis study tested an artificial intelligence system called GliomaAI-MG that analyzes routine MRI scans to detect a specific aggressive brain tumor type called molecular glioblastoma. Researchers used existing MRI data from 1,372 patients across 13 hospitals. The goal was to see h…
Sponsor: Deep Learning Institute of Radiological Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New quick MRI could speed up brain tumor diagnosis in kids
Diagnosis CompletedThis study tested a new, fast MRI sequence called Neuromix in 32 children with suspected or confirmed brain tumors. The goal was to see if the quick scan works as well as the standard, longer MRI. If it does, it could make scanning easier and less stressful for children.
Sponsor: Karolinska University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New PET scan may solve brain tumor puzzle: regrowth or side effect?
Diagnosis CompletedThis study looked at whether a special type of PET scan (using a tracer called FET) can accurately tell the difference between a returning brain tumor (glioma) and harmless changes caused by previous treatment. Researchers analyzed scans from 253 patients of all ages who had alre…
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New MRI technique may solve brain scan mystery after radiation
Diagnosis CompletedThis completed study tested whether a special type of MRI called dynamic susceptibility contrast (DSC) perfusion MRI can accurately tell the difference between radiation-induced brain damage and tumor regrowth in people whose cancer has spread to the brain. Eight patients who had…
Phase: NA • Sponsor: Emory University • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Which MRI scan best spots lung cancer spread to the brain?
Diagnosis CompletedThis study looked at 30 adults with lung cancer that had spread to the brain. Researchers compared two standard MRI sequences (T1 and T2*) to see which one better detects and tracks brain metastases after chemotherapy or targeted therapy. The goal is to improve diagnosis and moni…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New scan could reveal brain tumor aggression without surgery
Diagnosis CompletedThis study tested a special PET scan tracer called FLT in 50 adults with brain tumors (gliomas or metastases). The goal was to see if FLT-PET can measure how fast tumor cells are growing, which could help doctors diagnose and predict tumor behavior better than current scans like …
Phase: NA • Sponsor: University Hospital, Caen • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
Can a special PET scan outperform MRI for spotting brain tumors?
Diagnosis CompletedThis study tested whether a special PET scan (called 18F-DOPA PET-CT) can find brain metastases as well as or better than standard MRI in people with lung cancer, breast cancer, or melanoma. 32 adults with untreated brain metastases took part. The goal was to see if this PET meth…
Phase: NA • Sponsor: Institut Cancerologie de l'Ouest • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
New dye could sharpen PET scans for recurrent brain cancer
Diagnosis CompletedThis study tested whether a special dye called fluoroethyltyrosine (FET) can improve PET scans for detecting brain tumors that have come back. 143 people with suspected recurrent brain tumors received an injection of FET before their PET scan. The goal was to see if FET-PET could…
Phase: PHASE2 • Sponsor: Thomas Hope • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New scan method aims to sharpen brain tumor images
Diagnosis CompletedThis early study tested a new imaging technique that combines a special tracer ([18F]PARPi) with PET and MRI scans to get clearer pictures of brain tumors. Five adults with new or suspected returning brain tumors took part. The goal was to see how well the tracer highlights tumor…
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:03 UTC
-
New contrast agent shows promise for brain tumor MRI scans
Diagnosis CompletedThis completed Phase 3 trial tested whether Elucirem (gadopiclenol) provides better MRI images of brain gliomas compared to the standard contrast agent Dotarem. 138 adults with primary or recurrent brain tumors received one of the two agents during DSC-MRI perfusion scans. The ma…
Phase: PHASE3 • Sponsor: Guerbet • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
AI tool spots pneumonia risk after brain surgery
Diagnosis CompletedThis study tested a machine learning tool that uses routine medical data to predict pneumonia risk within the first week after brain tumor surgery. Researchers included over 1,800 adults having their first planned brain tumor removal. The goal was to see if the AI could help doct…
Sponsor: Ming Yang • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
New Gadolinium-Free MRI dye shows promise for brain scans
Diagnosis CompletedThis study tested a new MRI contrast agent called RVP-001, made with manganese instead of gadolinium, in 18 adults with known brain lesions (like tumors or multiple sclerosis). The goal was to see if it is safe and can detect lesions as well as current gadolinium-based dyes. Each…
Phase: PHASE2 • Sponsor: Reveal Pharmaceuticals Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 08:06 UTC
-
New PET tracer aims to light up hidden infections
Diagnosis CompletedThis early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
PET scan breakthrough: spotting brain tumors vs. Look-Alikes
Diagnosis CompletedThis study looked at whether a type of PET scan called FDOPA-PET can help doctors tell the difference between brain tumors and non-cancerous brain lesions. Researchers reviewed scans from 74 patients with suspected brain tumors. They measured how much of the tracer the lesions to…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
New PET technique may solve brain scan puzzle
Diagnosis CompletedThis study tested whether an early, quick PET scan using F-DOPA can help doctors tell the difference between a brain tumor coming back and damage from radiation therapy. Eight patients who already needed a PET scan for their brain metastases took part. The goal was to see if meas…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
New PET/MRI scan could spot elusive brain tumors in Cushing's patients
Diagnosis CompletedThis study tested whether a special scan called [11C]-Methionine PET/MRI can better locate tiny pituitary tumors that cause Cushing's disease. Standard MRI often misses these tumors, leading to risky exploratory surgery. The study involved 33 adults with confirmed Cushing's disea…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
New radioactive tracer could sharpen cancer scans
Diagnosis CompletedThis early-phase trial tested a new radioactive imaging agent called 68Ga-NOTA-SNA002 in 17 adults with solid tumors. The agent was injected into a vein, and researchers checked its safety, how it spreads in the body, and how well it shows up on PET scans. The goal was to see if …
Phase: PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Diagnosis
Last updated Jun 26, 2026 18:18 UTC
-
AI eye scan could diagnose brain diseases in seconds
Diagnosis CompletedResearchers tested an artificial intelligence program that analyzes retinal images to diagnose several nerve and brain conditions, such as optic neuropathy and brain tumors. The study used data from 693 patients with confirmed diagnoses. The goal is to create a fast triage tool f…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Diagnosis
Last updated Jun 26, 2026 14:30 UTC
-
New radioactive tracer tested for cancer imaging in tiny early trial
Diagnosis CompletedThis early-phase trial tested a single injection of a radioactive imaging agent called 68Ga-LNC1007 in 8 adults (healthy volunteers and solid tumor patients). The goal was to check its safety, how it moves through the body, and how well it shows up on scans. The study is already …
Phase: PHASE1 • Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD. • Aim: Diagnosis
Last updated Jun 26, 2026 12:39 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase: PHASE2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Phase: NA • Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Could a blood pressure pill shield brain cancer patients from memory loss?
Prevention CompletedThis pilot study tested whether ramipril, a drug typically used for high blood pressure, can help prevent memory loss in people with glioblastoma who are receiving brain radiation. 75 patients took ramipril daily during and after chemoradiation. Researchers measured memory and th…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
Exercise may boost memory in kids treated for brain cancer
Symptom relief CompletedThis study tested whether a 12-week physical activity program could improve memory and attention in children who had radiation for brain tumors. Thirty-six kids aged 8–17 who finished radiation at least a year ago took part. Half started the program right away, while the other ha…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Phase: NA • Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Simple skin care may shield kids from cancer drug side effects
Symptom relief CompletedThis study tested a preventive skin care routine in 14 children (ages 6 months to 18 years) with brain tumors who were receiving targeted therapy (BRAF, MEK, or Pan-RAF inhibitors). The goal was to see if gentle skin care and sun protection could reduce or prevent skin reactions …
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New drug may ease severe skin rashes in cancer patients
Symptom relief CompletedThis study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Can a video game sharpen your mind after cancer or ICU stay?
Symptom relief CompletedThis small study tested a virtual reality game called Hometown Bound in 9 adults with mild cognitive impairment after cancer or ICU stay. Participants played the game three times a week for four weeks. Researchers measured memory and thinking skills before and after using standar…
Phase: NA • Sponsor: University of Cincinnati • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Simple breathing exercises cut lung problems after brain surgery by more than half
Symptom relief CompletedAfter brain tumor surgery, some patients develop lung issues like pneumonia. This study tested a new nursing system that includes breathing exercises, early movement, and team care. In 165 patients, the new system reduced lung complications from 13.6% to 4.8% and helped patients …
Phase: NA • Sponsor: The Affiliated Brain Hospital of Nanjing Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Warm water on feet may ease Pre-Surgery jitters
Symptom relief CompletedThis study tested whether soaking feet in warm water for 20 minutes before pituitary tumor surgery helps patients feel less anxious and keeps vital signs stable. 100 adults were enrolled, with one group receiving the foot bath and the other standard care. Researchers measured anx…
Phase: NA • Sponsor: Trakya University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Brain games for young cancer survivors: a promising pilot study
Symptom relief CompletedThis study tested whether a computer-based cognitive training program could help children with brain tumors who had radiation therapy. 45 children were randomly assigned to either an adaptive or non-adaptive training program. The goal was to see if the training could improve thin…
Phase: NA • Sponsor: Children's Oncology Group • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New study tests better pain control during brain surgery
Symptom relief CompletedThis study looked at two ways to numb a nerve bundle in the face during pituitary gland surgery. The goal was to see which method reduces the amount of anesthesia needed during the operation. Sixty adults having this type of surgery took part. The results help doctors choose the …
Phase: NA • Sponsor: Donia Hany Saad • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Walking your way through chemo: study tests if steps keep treatment on track
Symptom relief CompletedThis study tested whether a simple walking program, guided by a fitness tracker, could help cancer patients tolerate their chemoradiotherapy without missing treatments. 166 adults with brain, head and neck, lung, gastrointestinal, or cervical cancer participated. Patients were gi…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can melatonin and a sedative stop brain surgery confusion?
Symptom relief CompletedThis study tested whether giving melatonin along with the sedative dexmedetomidine could lower the chance of post-operative delirium (confusion) after open brain surgery. 100 adults aged 30-60 took part. The goal was to see if the combination works better than dexmedetomidine alo…
Phase: PHASE4 • Sponsor: Ain Shams University • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Can a VR headset calm brain tumor Patients' anxiety?
Symptom relief CompletedThis study tested whether using a virtual reality (VR) headset at home could help reduce anxiety and distress in adults with primary brain tumors. Sixty-one participants used the VR headset for 4 weeks and filled out symptom questionnaires. The goal was to see if this approach is…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Numbing the scalp may beat opioids for brain surgery pain
Symptom relief CompletedThis study tested whether a scalp nerve block (injecting numbing medicine into the scalp) controls pain better than morphine during and after brain surgery. 62 adults having brain tumor surgery were randomly assigned to receive either a scalp block or morphine. Researchers measur…
Phase: PHASE4 • Sponsor: Aga Khan University • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
New tool aims to ease burden on brain cancer caregivers
Symptom relief CompletedThis study tested whether a web-based tool called eSNAP, combined with a caregiver navigator, could help family caregivers of brain cancer patients feel less anxious and burdened. The tool helps caregivers map out their support network, while the navigator provides guidance. Rese…
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Brain tumor patients get help for 'Chemo Brain' with new telehealth program
Symptom relief CompletedThis pilot study tested a telehealth program called C-SMART for people with primary brain tumors who have mild memory or thinking problems. The program combines cognitive rehabilitation with mindfulness training over 8 weekly sessions. Researchers enrolled 32 patients and caregiv…
Sponsor: Virginia Commonwealth University • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Could a common cholesterol drug protect cancer Patients' hearing?
Symptom relief CompletedThis study looked at whether taking statins (cholesterol-lowering drugs) can reduce hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect their ears fr…
Phase: PHASE1, PHASE2 • Sponsor: Minia University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Shea butter and niacinamide cream may ease itching for immunotherapy patients
Symptom relief CompletedThis study tested whether using creams with niacinamide and shea butter can prevent or reduce skin itching in cancer patients receiving immunotherapy. 130 adults with solid tumors starting checkpoint inhibitor treatment were randomly assigned to use either the test cream or a con…
Phase: NA • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Numbing the nose vs. the face: which controls surgery blood pressure better?
Symptom relief CompletedThis study tested two methods to keep blood pressure stable and reduce pain during pituitary tumor surgery. Sixty adults received either a numbing injection near the cheekbone or numbing medicine placed inside the nose. The goal was to see which approach better controls blood pre…
Phase: PHASE3 • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Opioid-Free anesthesia may keep blood pressure steady during brain surgery
Symptom relief CompletedThis study compared opioid-free anesthesia (using dexmedetomidine and lidocaine) to standard opioid anesthesia in 86 adults having brain tumor surgery. The goal was to see if the opioid-free approach better controlled blood pressure during stressful moments like drilling into the…
Phase: NA • Sponsor: Kasr El Aini Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Can reiki ease cancer pain? small study says maybe
Symptom relief CompletedThis study tested whether Reiki, a relaxation therapy where a practitioner places hands on or near the body, could help cancer patients with symptoms like pain and fatigue. Ten adults with cancer who had at least three bothersome symptoms received up to six Reiki sessions. Resear…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Talking therapy shows promise for brain cancer distress
Symptom relief CompletedThis study tested a therapy called Managing Cancer and Living Meaningfully (CALM) to see if it helps people with brain cancer feel less distressed. 60 adults with brain tumors or brain metastases who had high depression or death anxiety took part. The study measured how many peop…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Brain cancer survivors team up with carers to tackle 'chemo brain'
Symptom relief CompletedThis study tested a program called ImPACT for brain cancer survivors who have trouble with thinking and memory. The program pairs each survivor with a carer to identify strengths and challenges, and create practical strategies for daily life. The trial enrolled 27 survivors and t…
Phase: NA • Sponsor: Aarhus University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
VR movies calm cancer patients before radiation
Symptom relief CompletedThis study tested whether watching 360° virtual reality movies can reduce fear and anxiety in cancer patients about to start radiation therapy. 292 adults with breast, lung, prostate, head and neck cancer, or brain tumors participated. Patients watched a VR movie and then filled …
Phase: NA • Sponsor: Maastricht Radiation Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Brain tumor insomnia targeted by CBT in new pilot study
Symptom relief CompletedThis study tested a type of talk therapy called Cognitive Behavioral Therapy for Insomnia (CBT-I) in 70 people with brain tumors who also had trouble sleeping. The therapy involved six weekly group sessions delivered online. The main goal was to see if the approach was practical …
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New online program eases Kids' cancer return to school
Symptom relief CompletedThis study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…
Phase: NA • Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New study tests monthly day care for advanced cancer patients
Symptom relief CompletedThis study looked at whether monthly visits to a hospital day care that includes palliative care can improve quality of life for adults with advanced cancer. 144 patients with a life expectancy between 2 and 12 months took part. Researchers measured changes in quality of life, fa…
Phase: NA • Sponsor: Institut Curie • Aim: Symptom relief
Last updated Jun 26, 2026 18:50 UTC
-
New study measures how brain radiation affects thinking and daily life
Knowledge-focused CompletedThis study looked at whether standard radiation treatment for cancer that has spread to the brain causes changes in thinking skills like memory and attention. 35 adults with brain metastases received radiation and took tests and surveys before and after treatment. The goal was to…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Large study digs into rare brain tumors to uncover clues
Knowledge-focused CompletedThis study gathered information from 326 adults with rare central nervous system tumors, such as medulloblastoma and ependymoma. Participants completed surveys about their symptoms, treatments, and lifestyle, and provided a saliva sample for genetic analysis. The goal was to lear…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists uncover genetic secrets behind rare hormone disorders
Knowledge-focused CompletedThis study looked at nearly 1,400 people with rare conditions like PPNAD, Carney Complex, and Peutz-Jeghers syndrome. The goal was to find the genetic causes and link them to specific symptoms. Researchers used clinical exams and genetic testing to better understand how these dis…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Graphene brain sensor tested in humans for first time
Knowledge-focused CompletedThis study tests a new graphene-based electrode array used during brain tumor surgery to map brain activity. Ten participants will have the device used alongside standard monitoring to check its safety and how well it records brain signals. If awake during surgery, they may do si…
Phase: NA • Sponsor: University of Manchester • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Researchers bank samples to unlock secrets of brain tumors
Knowledge-focused CompletedThis completed study enrolled over 1,200 people with brain or spinal cord tumors to collect medical information, blood samples, and tumor tissue. The goal was to better understand these cancers and identify promising areas for future research. Participants also received guidance …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New imaging method could reduce need for brain tumor biopsies
Knowledge-focused CompletedThis completed study looked at whether a special PET scan technique called radiomics can help doctors figure out the type and behavior of brain tumors (gliomas) without needing a surgical biopsy. Researchers analyzed scans from 1000 patients who had already received an 18F-FDOPA …
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study tracks Radiation's toll on Kids' brains
Knowledge-focused CompletedThis study followed 76 children with brain tumors to learn how radiation therapy affects their quality of life, thinking, and body functions over time. Researchers collected blood, urine, and MRI scans before and after treatment, along with tests of memory, behavior, vision, and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study: can targeted radiation save thinking skills in patients with multiple brain tumors?
Knowledge-focused CompletedThis study compared two types of radiation for people with 11 to 20 brain tumors that spread from other cancers. One group got Gamma Knife radiosurgery, which targets each tumor precisely. The other got whole brain radiation, which treats the entire brain. The goal was to see whi…
Phase: NA • Sponsor: Elisabeth-TweeSteden Ziekenhuis • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Massive study tests yearly brain scans for lung cancer patients
Knowledge-focused CompletedThis study analyzed health records from over 229,000 people with newly diagnosed lung cancer in Korea to see if getting a brain MRI every year helps find cancer that has spread to the brain. The goal was to learn whether these scans catch brain metastases earlier, when they might…
Sponsor: Samsung Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study reveals how brain scans predict surgery outcomes for pituitary tumors
Knowledge-focused CompletedThis study looked at 49 people with masses in the sellar region of the brain (near the pituitary gland). Researchers compared MRI scans before surgery with the final diagnosis after surgery to see how well imaging predicts the type of tumor. The goal was to improve diagnosis and …
Sponsor: Arab Board of Neurosurgery • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Brain surgeons pinpoint the 'Arrival Time' region during awake operations
Knowledge-focused CompletedThis study investigates which parts of the brain help us judge when a moving object will reach us, a skill used in daily life. Researchers test patients during awake brain surgery for tumor removal, using a simple task where they estimate when a disappearing object would have mad…
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Study reveals why immunotherapy works differently in liver, lung, and brain tumors
Knowledge-focused CompletedThis study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…
Sponsor: Wenlong Zhong, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
AI learns to spot cancer pain from faces and voices
Knowledge-focused CompletedThis study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Eye test may spot brain trouble
Knowledge-focused CompletedThis small pilot study tested whether a non-invasive eye scan called OCTA can detect changes in the brain related to stroke and other neurological conditions. Researchers compared eye scans from 7 people with brain diseases and healthy volunteers. The goal was to gather early dat…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Massive cancer registry tracks genetic Testing's Real-World impact
Knowledge-focused CompletedThis completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Brain radiation may erase personal memories, study warns
Knowledge-focused CompletedThis study looks at how radiation therapy for brain tumors like meningioma or pituitary adenoma might affect autobiographical memory—the memories of your life events. Researchers will ask 17 patients to complete memory tests one and two years after treatment. The goal is to see i…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New program aims to better involve relatives in brain injury care
Knowledge-focused CompletedThis study developed and tested a program to help nurses better support relatives of patients with acquired brain injury or malignant brain tumors. The program included nurse training, a dialog tool, a peer support list, videos, and documentation guidelines. Researchers tested it…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Genetic testing could unlock new treatments for kids with brain cancer
Knowledge-focused CompletedThis study tested whether a detailed genetic analysis of tumor tissue could find treatment targets in 80 children with recurrent or very high-risk brain tumors. The goal was to see if this approach is practical and can help doctors choose personalized therapies. No new drugs were…
Phase: NA • Sponsor: Masaryk University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New drug tracking study offers no cure, but key insights for future cancer treatments
Knowledge-focused CompletedThis study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Brain surgery fluid strategy tested in 32 patients
Knowledge-focused CompletedThis study tested two different fluid management approaches during brain tumor removal surgery. 32 adults were monitored to see which method led to better recovery, measured by blood lactate levels. The goal was to find the best way to give fluids during surgery to improve patien…
Phase: NA • Sponsor: Cairo University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for biomarkers to personalize proton beam cancer therapy
Knowledge-focused CompletedThis completed study enrolled 84 people with brain tumors, meningioma, or high-grade sarcoma who received proton beam therapy. Researchers analyzed tumor and blood samples to find biomarkers that might predict how well the cancer responds to treatment. The goal is to eventually h…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study aims to measure what matters most for kids with tough brain cancers
Knowledge-focused CompletedThis completed study looked at how re-irradiation affects the quality of life and symptoms of 20 children with diffuse intrinsic pontine glioma (DIPG) or recurrent brain tumors, as well as their caregivers. Researchers used surveys to track physical, emotional, and social well-be…
Sponsor: University of Calgary • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Scientists hunt for biomarkers to predict radiation damage
Knowledge-focused CompletedThis study analyzed blood, urine, and tissue samples from 273 adults with brain or lung cancer who were receiving radiation therapy. The goal was to find biological markers that could predict which patients are more likely to develop serious side effects from radiation, such as l…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Phase: NA • Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Glow-in-the-Dark dyes may help surgeons remove more brain tumor
Knowledge-focused CompletedThis study looked back at medical records of 41 patients who had surgery for aggressive brain tumors (high-grade gliomas). Some surgeries used fluorescent dyes that make tumor tissue glow, helping surgeons tell it apart from healthy brain. The goal was to see if using these dyes …
Sponsor: Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
New study tracks hidden heart and bone risks in Cushing's disease
Knowledge-focused CompletedThis study followed 80 people with newly diagnosed Cushing's disease for three years to see how the disease affects the heart, bones, metabolism, and quality of life. Researchers used blood tests, heart scans, bone density tests, and questionnaires to track complications before a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Brain surgery breakthrough? scientists watch blood Pressure's role in bleeding
Knowledge-focused CompletedThis study looked at 160 adults having planned brain surgery to see if raising blood pressure during the operation makes it harder for surgeons to stop bleeding. Doctors increased blood pressure slightly with a medicine and noted if extra steps were needed to control bleeding. Th…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Brain tumor patients and caregivers speak out: what they really need
Knowledge-focused CompletedThis completed study from Mayo Clinic interviewed 33 adults with brain or central nervous system (CNS) tumors, along with their caregivers, to learn about their biggest challenges and needs. The goal was to identify areas where doctors and healthcare teams can offer better suppor…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Autopsy study sheds light on brain cancer Therapy's effects
Knowledge-focused CompletedThis study looked at brain tissue from 20 glioblastoma patients who had received Tumor Treating Fields (TTFields) therapy. Researchers examined the tissue after the patients died to see how the treatment affected tumor cells. The goal was to find patterns that could help doctors …
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Eye scan may forecast vision after brain surgery
Knowledge-focused CompletedThis study tested whether a type of eye scan called OCT-angiography can predict how well vision will recover after surgery to remove a pituitary tumor. Researchers compared the scan results with standard vision tests in 21 patients. The goal was to see if the scan could serve as …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Childhood brain tumor survivors face hidden hormone risks
Knowledge-focused CompletedThis study examined 12 childhood brain tumor survivors to understand long-term hormone and metabolic problems. Researchers checked for issues like growth hormone deficiency, thyroid problems, obesity, and abnormal cholesterol. The goal is to help doctors better monitor and manage…
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Michigan study tests ways to boost genetic testing in cancer patients
Knowledge-focused CompletedThis study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to se…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Can adding radiation to immunotherapy help advanced cancer patients? new study explores safety and 'Abscopal' effects
Knowledge-focused CompletedThis study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New study tackles bone pain caused by chemo-boosting drug
Knowledge-focused CompletedThis study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Nutrition score may predict brain surgery outcomes
Knowledge-focused CompletedThis study explored whether a nutritional index (PNI) can predict death and other complications after brain tumor surgery. Researchers analyzed data from over 3,200 adults who had surgery at a major hospital in South Korea. The goal was to see if this simple blood-based score cou…
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Discarded tumor tissue yields clues for future brain cancer therapies
Knowledge-focused CompletedThis study looked at leftover tumor tissue and blood samples from 141 adults with glioblastoma or other solid tumors who were having surgery. The goal was to measure cell counts and viability to help scientists design better treatments for brain cancer and other solid tumors in t…
Sponsor: Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Brain tumor Survivors' social lives under the microscope
Knowledge-focused CompletedThis study looked at how children who survived brain tumors interact with others. Researchers tested their thinking and social skills to see what helps or hurts their friendships. The goal was to learn more, not to test a new treatment.
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Emergency doctors learn to read brain scans with online training
Knowledge-focused CompletedThis study looked at whether online training can improve how well emergency department doctors interpret CT head scans. 173 clinicians from 6 UK hospitals took part. One group received training early, while a control group got it later. The goal was to see if training boosts accu…
Phase: NA • Sponsor: Oxford University Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug interaction study: will antibiotics or antifungals change its effects?
Knowledge-focused CompletedThis study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
AI model predicts brain fog risk in kids after tumor surgery
Knowledge-focused CompletedThis study looked at medical records of 600 children who had brain tumor surgery to find out which kids might have long-term thinking or memory problems. Researchers used machine learning to create a tool that predicts this risk based on brain scans, tumor details, and treatment …
Sponsor: West China Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
450 brain tumor patients reveal key survival clues
Knowledge-focused CompletedThis study looked back at 450 people who had surgery for a rare type of brain tumor (cerebellar glioma). Researchers wanted to see if where the tumor was located and its genetic makeup could predict how much of the tumor could be safely removed and how long patients lived. The go…
Sponsor: West China Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Cancer patients happier getting immunotherapy at home?
Knowledge-focused CompletedThis French study asked 49 cancer patients how they felt about switching from hospital to home-based immunotherapy. The goal was to see if home treatment improved their satisfaction with care. It was an observational study, meaning no new treatments were tested—just patient exper…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists try out new tools to feel how hard tumors are
Knowledge-focused CompletedThis study tested two new methods to measure pressure and stiffness inside solid tumors in 27 patients. One method uses a thin catheter to measure pressure directly, and the other uses sound waves like an ultrasound to check stiffness. The goal was to see if these measurements co…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Chemo nausea still a problem despite standard care, study finds
Knowledge-focused CompletedThis study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Your iPhone could be your next cancer symptom tracker
Knowledge-focused CompletedThis study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Question list boosts cancer Patients' confidence and reduces anxiety
Knowledge-focused CompletedThis study tested whether giving cancer patients a list of questions to ask their doctors helps them feel more empowered and less anxious. About 96 patients, along with nurses and doctors, took surveys and shared their experiences. The goal is to improve communication and make pa…
Phase: NA • Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy side effects under the microscope: new study monitors autoantibodies
Knowledge-focused CompletedThis completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies…
Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
App vs. paper: which diary boosts cancer pill adherence?
Knowledge-focused CompletedThis study tested whether an electronic diary app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either the app or a paper diary to track th…
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New registry tracks young brain tumor patients to boost research
Knowledge-focused CompletedThis registry collected information and biological samples from 354 children and young adults diagnosed with certain brain tumors like medulloblastoma and ependymoma. The goal was to improve diagnostic standards through expert review and to gather data for future research. No new…
Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Virtual reality test reveals hidden memory damage in cured Cushing's patients
Knowledge-focused CompletedThis study looked at whether people who have been cured of Cushing's disease for at least a year still have memory problems. Researchers used a special virtual reality test to check memory, along with standard tests. The goal was to better understand these lasting effects and imp…
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Scientists map brain tumor genetics using blood and spinal fluid
Knowledge-focused CompletedThis study examined genetic and epigenetic changes in brain metastases from solid cancers. Researchers collected tumor tissue, blood, and spinal fluid from 21 patients during surgery to compare molecular profiles. The goal was to see if liquid biopsies could reliably reflect the …
Phase: NA • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Real-World data on firmonertinib for lung cancer that spread to the brain
Knowledge-focused CompletedThis study looked back at medical records of 300 people with EGFR-positive non-small cell lung cancer that had spread to the brain or spinal cord. All patients were treated with the drug firmonertinib. Researchers analyzed how long the drug controlled brain tumors and explored wh…
Sponsor: Beijing Tiantan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Protein map of rare childhood cancer could reveal new attack points
Knowledge-focused CompletedThis study looked at protein patterns in tumor samples from 44 children with a rare cancer called rhabdoid tumor. Researchers used advanced techniques to see how tumors differ from each other. The goal was to find new targets for future treatments. The study is complete and did n…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Cancer patients with COVID: do early antiviral drugs help?
Knowledge-focused CompletedThis completed study looked at how well early COVID-19 antiviral therapies work in cancer patients. Researchers tracked 112 patients with solid tumors who received these treatments to see how many needed hospitalization within 14 days. The goal is to fill knowledge gaps and impro…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Proton Therapy's Long-Term effects on Kids' brains under the microscope
Knowledge-focused CompletedThis study followed 155 children with brain or central nervous system tumors who received proton radiation therapy at Massachusetts General Hospital. Researchers measured changes in thinking skills, behavior, and use of special education services one year or more after treatment.…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Can a Child's tumor DNA guide better cancer treatment?
Knowledge-focused CompletedThis study tested whether analyzing the DNA and RNA of a child's tumor could help doctors choose personalized treatments. It included 186 children with relapsed or hard-to-treat cancers like neuroblastoma and brain tumors. The goal was to see if this approach was feasible and saf…
Phase: NA • Sponsor: Giselle Sholler • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Gene-Based dosing study aims to make cancer drug safer
Knowledge-focused CompletedThis early-phase study tested the safety and drug levels of belinostat in 17 patients with advanced solid tumors or blood cancers that had not responded to prior treatments. Researchers grouped patients by their UGT1A1 gene type to see if genetic differences affect how the drug i…
Phase: PHASE1 • Sponsor: Acrotech Biopharma Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Should all young cancer patients get genetic testing? study investigates
Knowledge-focused CompletedThis study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …
Phase: NA • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
No-Mask radiation therapy: a comfortable alternative for head and neck cancer patients?
Knowledge-focused CompletedThis pilot study tested a new maskless immobilization device (MID) for patients with head and neck cancers or brain tumors undergoing radiation therapy. The goal was to see if the device could keep patients as still and accurate as the standard thermoplastic mask. Only 12 patient…
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
New radiation technique for brain tumors under the microscope
Knowledge-focused CompletedThis completed study gathered information from nearly 1,000 patients who received or were scheduled to receive HyperArc stereotactic radiosurgery, a precise radiation treatment for brain tumors. The goal was to collect data on survival and tumor control to compare HyperArc with o…
Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Drug interaction study tests liver enzyme effects on cancer treatment
Knowledge-focused CompletedThis study looked at how bosentan, a drug that affects liver enzymes, changes the levels of the cancer drug lurbinectedin in the blood. Eleven adults with advanced solid tumors received lurbinectedin alone and with bosentan. The goal was to see if bosentan alters how the body pro…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:46 UTC
-
Soft brain probe tested in humans for first time
Knowledge-focused CompletedThis first-in-human study tested a new soft neural probe in 5 adults already scheduled for brain surgery to remove a tumor or epileptic tissue. The probe was inserted into the part of the brain being removed to see if it could be placed safely and record electrical signals. Parti…
Phase: NA • Sponsor: Axoft, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:33 UTC
-
New registry aims to sharpen use of precision radiation for cancer
Knowledge-focused CompletedThis study created a registry of 149 cancer patients who received a precise type of radiation called SBRT. The goal was to track how doctors use this treatment in four different situations: for cancer that has spread to a few spots, after chemotherapy, before starting chemotherap…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:50 UTC
-
New data on targeted breast cancer drugs from everyday practice
Knowledge-focused CompletedThis completed study looked at 312 patients with advanced breast cancer who received either trastuzumab deruxtecan or sacituzumab govitecan. Researchers collected real-world information on side effects and how long the cancer was kept under control. The goal was to see how these …
Sponsor: Hellenic Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:24 UTC
-
Brain scans reveal hidden memory damage in childhood cancer survivors
Knowledge-focused CompletedThis study looked at how radiation therapy for pediatric brain cancer affects memory and brain structure in children, teens, and young adults. Researchers used MRI scans and memory tests to compare 60 participants. The goal is to better understand which brain areas are harmed by …
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:09 UTC
-
New PET/MRI scan could help kids with brain tumors get better treatment
Knowledge-focused CompletedThis study tested whether a special type of brain scan (PET/MRI) can be used in children aged 5-17 with brain tumors. The scan combines two imaging techniques to give doctors more information about the tumor. Only 15 children took part, and the main goal was to see if the scan wa…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:40 UTC
-
New brain scan could sharpen surgery for glioma patients
Knowledge-focused CompletedThis pilot study tested whether a special PET scan using 18F-FDOPA can help doctors better plan surgery and radiation for people with newly diagnosed brain tumors (gliomas). Twenty-four adults took part at Mayo Clinic. The goal was to see if the scan provides useful information b…
Phase: EARLY_PHASE1 • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:06 UTC
-
Small study tests drug interaction in advanced cancer patients
Knowledge-focused CompletedThis Phase 1 study looked at how the antifungal drug itraconazole affects the levels of the cancer drug lurbinectedin in 14 patients with advanced solid tumors. The goal was to understand potential drug interactions, not to treat the cancer. Results may guide future dosing and sa…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:50 UTC
-
New ultrasound technique could help surgeons see brain activity in real time
Knowledge-focused CompletedThis study tested a new, highly sensitive ultrasound technique to map brain activity during surgery in 23 adults with brain tumors or lesions. The method aims to provide real-time images of blood flow changes linked to brain function, without needing contrast agents. Researchers …
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:48 UTC